IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder
This study has been completed.
Sponsor:
Shaare Zedek Medical Center
Information provided by:
Shaare Zedek Medical Center
ClinicalTrials.gov Identifier:
NCT00364702
First received: August 15, 2006
Last updated: August 16, 2011
Last verified: July 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Using a virtual reality program in screening and treatment of ADHD.
| Condition | Intervention | Phase |
|---|---|---|
| ADHD | Drug: methylphenidate | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Factorial Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder |
Resource links provided by NLM:
Further study details as provided by Shaare Zedek Medical Center:
Primary Outcome Measures:
- Virtual Reality program test results
| Estimated Enrollment: | 40 |
| Study Start Date: | August 2006 |
| Study Completion Date: | July 2007 |
| Primary Completion Date: | July 2007 (Final data collection date for primary outcome measure) |
Virtual Reality is a novel program designed to imitate a real classroom environment including various distractions. It includes a head monitor to track eye movements Children aged 10-20 years with ADHD will use the program with and without methylphenidate(1 mg/kg). Their results will be compared to a control group.
Parental consent will be obtained.
Eligibility| Ages Eligible for Study: | 10 Years to 20 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
Clinical diagnosis of ADHD-DSM4 criteria AGE 10-20 YEARS normal neurological examination IQ>80
Exclusion Criteria:
ABNORMAL NEUROLOGICAL STATUS
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00364702
Please refer to this study by its ClinicalTrials.gov identifier: NCT00364702
Locations
| Israel | |
| Shaari Zedek Pediatric Neurology Unit | |
| Jerusalem, Israel, 91031 | |
Sponsors and Collaborators
Shaare Zedek Medical Center
Investigators
| Study Chair: | V. Gross, Prof/ md | Shaari Zedek Pediatric Neurology Unit |
More Information
| ClinicalTrials.gov Identifier: | NCT00364702 History of Changes |
| Other Study ID Numbers: |
45/04 |
| Study First Received: | August 15, 2006 |
| Last Updated: | August 16, 2011 |
Keywords provided by Shaare Zedek Medical Center:
|
Virtual Reality ADHD Methylphenidate |
Additional relevant MeSH terms:
|
Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents |
ClinicalTrials.gov processed this record on June 26, 2017